[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2129893T3 - Dinucleosido-5',5'-pirofosfatos. - Google Patents

Dinucleosido-5',5'-pirofosfatos.

Info

Publication number
ES2129893T3
ES2129893T3 ES95943516T ES95943516T ES2129893T3 ES 2129893 T3 ES2129893 T3 ES 2129893T3 ES 95943516 T ES95943516 T ES 95943516T ES 95943516 T ES95943516 T ES 95943516T ES 2129893 T3 ES2129893 T3 ES 2129893T3
Authority
ES
Spain
Prior art keywords
ribosida
dideoxi
pyrophosphates
dinucleoside
hipoxantina
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95943516T
Other languages
English (en)
Inventor
Flora Antonio De
Umberto Benatti
Marco Giovine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biosearch Italia SpA
Universita degli Studi di Genova
Original Assignee
Biosearch Italia SpA
Universita degli Studi di Genova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosearch Italia SpA, Universita degli Studi di Genova filed Critical Biosearch Italia SpA
Application granted granted Critical
Publication of ES2129893T3 publication Critical patent/ES2129893T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Dental Preparations (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Photoreceptors In Electrophotography (AREA)

Abstract

SE DESCRIBEN 5'',5''-PIROFOSFATOS DE NUCLEOSIDOS QUE OCURREN DE FORMA NO NATURAL SELECCIONADOS DE TIAMINA-3''-AZIDO-2'',3''DIDEOXID-RIBOSIDA, 5-FLUOURACIL-2''-DEOXI-D-RIBOSIDA, URACIL-3''-AZIDO2''.3''-DIDEOXI-D-RIBOSIDA, GUANINA-2'',3''-DIDEOXI-D-RIBOSIDA, HIPOXANTINA-2'',3''-D-RIBOSIDA, CITOSINA-2'',3''-D-RIBOSIDA, Y ADENINA-2'',3''-D-RIBOSIDA, ASI COMO SU FABRICACION Y USO COMO AGENTES TERAPEUTICOS CONTRA TUMORES E INFECCIONES RETROVIRALES INCLUYENDO INFECCIONES POR VIH. LOS COMPUESTOS PUEDEN SER ADMINISTRADOS COMO LOS INGREDIENTES ACTIVOS DE COMPOSICIONES FARMACEUTICAS O COMO PRO-FARMACOS ENCAPSULADOS EN PORTADORES BIOLOGICOS, P. EJ., ERITROCITOS TRANSFORMADOS, PARA FIJAR LA POBLACION DE CELULA ESPECIFICA RESPONSABLE DEL DESARROLLO DE LOS TRASTORNOS PATOLOGICOS.
ES95943516T 1994-07-15 1995-07-10 Dinucleosido-5',5'-pirofosfatos. Expired - Lifetime ES2129893T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94202059 1994-07-15

Publications (1)

Publication Number Publication Date
ES2129893T3 true ES2129893T3 (es) 1999-06-16

Family

ID=8217039

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95943516T Expired - Lifetime ES2129893T3 (es) 1994-07-15 1995-07-10 Dinucleosido-5',5'-pirofosfatos.

Country Status (15)

Country Link
US (2) US6040297A (es)
EP (1) EP0773951B1 (es)
JP (1) JPH10502655A (es)
AT (1) ATE177431T1 (es)
AU (1) AU688552B2 (es)
CA (1) CA2195091A1 (es)
DE (1) DE69508255T2 (es)
ES (1) ES2129893T3 (es)
FI (1) FI970081A (es)
HU (1) HUT76331A (es)
IL (1) IL114520A0 (es)
NO (1) NO965483L (es)
NZ (1) NZ290127A (es)
WO (1) WO1996002554A1 (es)
ZA (1) ZA955826B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100606131B1 (ko) 1997-02-06 2006-07-31 인스파이어 파마슈티컬스 인코퍼레이티드 디뉴클레오티드 및 그의 용도
US6596725B2 (en) 1997-02-10 2003-07-22 Inspire Pharmaceuticals, Inc. Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
US7078391B2 (en) * 1997-02-10 2006-07-18 Inspire Pharmaceuticals, Inc. Method of treating edematous retinal disorders
US7223744B2 (en) * 1997-02-10 2007-05-29 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
US6818629B2 (en) 1997-02-10 2004-11-16 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-) tetraphosphate
WO2001012644A1 (en) * 1999-08-17 2001-02-22 Adani, Alexander Dinucleoside 5',5'-tetraphosphates as inhibitors of viral reverse transcriptases and viruses
BRPI0003386B8 (pt) * 2000-08-08 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda pró-droga homo ou heterodiméricas úteis no tratamento de doenças ou disfunções mediadas por fosfodiesterases; composições farmacêuticas contendo a pró-droga ou seus sais farmacêuticos aceitáveis; processo de obtenção destas pró-drogas
US6867199B2 (en) 2000-08-21 2005-03-15 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapeutic use
US6555675B2 (en) 2000-08-21 2003-04-29 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists
US7790037B2 (en) * 2003-06-25 2010-09-07 University of Pittsburgh—of the Commonwealth System of Higher Education Separation of compounds using tagging moieties including varying numbers of repeat units
US20230000894A1 (en) * 2019-09-05 2023-01-05 Mitorainbow Therapeutics, Inc. Treating mitochondrial dna depletion disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3321462A (en) * 1963-07-15 1967-05-23 Syntex Corp Process for the preparation of nucleoside polyphosphates
US3506478A (en) * 1968-08-29 1970-04-14 Budd Co Method of balancing a brake drum
US4855304A (en) * 1985-01-10 1989-08-08 Repligen Corporation Dinucleoside pyrophosphates and pyrophosphate homologs as plant antivirals
US5159067A (en) * 1987-01-28 1992-10-27 University Of Georgia Research Foundation Inc. 5'-Diphosphohexose nucleoside pharmaceutical compositions
CA1330794C (en) * 1987-03-27 1994-07-19 Phillip Frost Anti-viral compounds, dosage forms and methods
IL86650A0 (en) * 1987-06-30 1988-11-30 Biophor Corp Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane
EP0375183A1 (en) * 1988-12-05 1990-06-27 Schering Corporation Antiviral dimers and trimers
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
DE69127615T2 (de) * 1991-06-14 1998-03-19 Europ Communities Transformierte Erythrozyten, Verfahren zu deren Herstellung, und ihre Verwendung in pharmazeutischen Zusammensetzungen
US5521161A (en) * 1993-12-20 1996-05-28 Compagnie De Developpment Aguettant S.A. Method of treating HIV in humans by administration of ddI and hydroxycarbamide

Also Published As

Publication number Publication date
IL114520A0 (en) 1995-11-27
JPH10502655A (ja) 1998-03-10
ZA955826B (en) 1996-02-21
MX9700360A (es) 1998-03-31
CA2195091A1 (en) 1996-02-01
US6080731A (en) 2000-06-27
DE69508255T2 (de) 1999-10-14
EP0773951A1 (en) 1997-05-21
NO965483L (no) 1997-01-28
WO1996002554A1 (en) 1996-02-01
HUT76331A (en) 1997-08-28
NZ290127A (en) 1998-05-27
DE69508255D1 (de) 1999-04-15
EP0773951B1 (en) 1999-03-10
FI970081A0 (fi) 1997-01-08
FI970081A (fi) 1997-01-08
HU9700118D0 (en) 1997-02-28
ATE177431T1 (de) 1999-03-15
US6040297A (en) 2000-03-21
AU3076695A (en) 1996-02-16
AU688552B2 (en) 1998-03-12
NO965483D0 (no) 1996-12-19

Similar Documents

Publication Publication Date Title
BR9714082A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto.
DE69912606D1 (de) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol-derivate
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
BR9814857A (pt) Processos para tratar leucemia, câncer sólido eleucemia, linfoma ou tumores sólidos em umhumano, e para fabricar uma composiçãofarmacêutica estéril, e, a respectiva composiçãofarmacêutica estéril
ATE49962T1 (de) Taxal-derivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen.
BR0109107A (pt) Usos terapêuticos de mediadores ppar
GT199700089A (es) Derivados 6.6 o 6.7 -biciclicos sustituidos que contienen pirido o pirimido.
AR004134A1 (es) Derivados 2-amino-6-anilino-purina y procedimiento y nuevos intermediarios para su preparacion, formulaciones farmaceuticas que comprenden talesderivados y el uso de estos derivados como medicamentos.
AR003938A1 (es) Compuestos triciclicos de urea utiles para la inhibicion de la funcion de la proteina g y para tratamiento de enfermedades proteoliticas, composicionfarmaceutica, y el uso de los mismos para la preparacion de medicamentos.
ES2161085T3 (es) Formulaciones que contienen oxaliplatino.
ES2037013T3 (es) Procedimiento para preparar tieno-1,4-diazepinas.
IS3284A7 (is) Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
ES2009723T3 (es) Derivados de acidos biliares, procedimientos para la preparacion de los mismos y composiciones farmaceuticas conteniendolos.
AR241082A1 (es) Nuevos derivados de pirazol utiles como agentes herbicidas, las composiciones herbicidas que los contienen y los procedimientos para producir estos derivados de pirazol".
ES2129893T3 (es) Dinucleosido-5',5'-pirofosfatos.
ES2052732T3 (es) 2',3'-didesoxi-3'-fluorotimidina y compuestos afines para el tratamiento de infecciones por adenovirus.
ES2159403T3 (es) Poliuretanos termoplasticos que contienen principios activos.
CO4940430A1 (es) Compuestos policiclicos que contienen estaurosporina hidrogenada con propiedades farmacologicas convenientes y un efecto inhibidor sobre el crecimiento de las celulas tumorales
FI962550A (fi) Deuterisoidut vaikuttavat aineet transdermaalisessa käyttötarkoituksessa
IT1213323B (it) Composizione per uso locale ad atti vita' spermicida virulicida ,disinfettante e/o battericida
ES2054650T3 (es) Fenilacetonitrilos basicamente substituidos, su obtencion y medicamentos que los contienen.
BR0009194A (pt) Composição do resorcinol
ES2053535T3 (es) Derivados heterociclicos de cinco miembros de n,n'-diacilhidrazinas n' sustituidas.
ES2059633T3 (es) 2-terc.-butil-4-cloro-5-(4-terc.-butilbenciltio)-3(2h)-piridazinona para la lucha contra los moluscos.
ATE22282T1 (de) Pentacycloundecan derivate, verfahren zu ihrer herstellung, und diese enthaltende pharmazeutische zusammensetzungen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 773951

Country of ref document: ES